Future Trends in Cancer Prevention and Interception in Cancer Predisposition Syndromes: Leveraging Insights From High‐Risk Populations
International Journal of Cancer · 31.07.2026
DOI: 10.1002/ijc.70674 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Cancer, online erschienen am 31.07.2026. Verfasst von Yiming Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, Ontario, Canada. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 90 Literaturangaben. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Cancer predisposition syndromes (CPS), arising from germline pathogenic variants in cancer predisposition genes (CPGs), are increasingly recognized as major contributors to pediatric and adult malignancies. Recent genomic advances have significantly enhanced the diagnosis, surveillance, and management of CPS, providing a unique framework for cancer prevention and interception of pre‐malignant lesions. Increased utilization of comprehensive germline and tumor‐normal sequencing has improved diagnostic precision, allowing early identification of at‐risk individuals, including those with and without a family history of cancer. Integration of genome and long‐read sequencing technologies further increases diagnostic yield by detecting structural and noncoding variants. Early diagnosis strategies, such as newborn screening, have demonstrated clinical utility and cost‐effectiveness in population studies, such as the TP53 R337H variant newborn screening in Brazil. Evidence‐based surveillance protocols, supported by outcome data, have led to earlier tumor detection and improved survival. Novel ‘liquid biopsy’ approaches offer minimally invasive tools for surveillance, with the potential to detect malignancies prior to radiologic findings. Beyond early detection, emerging strategies aim to intercept tumor development. Medical prevention strategies such as metformin in Li–Fraumeni syndrome and aspirin in Lynch syndrome show promise in modifying cancer risk. Immunoprevention, particularly neoantigen‐targeted vaccines in mismatch repair‐deficient tumors, is an evolving frontier with preliminary evidence of immunogenicity and safety. Together, these advances represent a paradigm shift in CPS management, offering a model for precision cancer prevention. Continued international collaboration, longitudinal studies, and health economic evaluations will be critical to translating these innovations into clinical and public health practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, Ontario, Canada.
- Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada.
- Department of Pediatrics, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Department of Medical Biophysics, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
ORCID-Profile: Steven M Lipkin
Förderung
- NCI NIH HHS
Zitieren
APA
Wang, Y., Malkin, D., & Lipkin, S. M. (2026). Future Trends in Cancer Prevention and Interception in Cancer Predisposition Syndromes: Leveraging Insights From High‐Risk Populations. International Journal of Cancer. https://doi.org/10.1002/ijc.70674
Vancouver
Wang Y, Malkin D, Lipkin SM. Future Trends in Cancer Prevention and Interception in Cancer Predisposition Syndromes: Leveraging Insights From High‐Risk Populations. International Journal of Cancer. 2026. doi:10.1002/ijc.70674
BibTeX
@article{Wang2026,
author = {Wang, Yiming and Malkin, David and Lipkin, Steven M},
title = {Future Trends in Cancer Prevention and Interception in Cancer Predisposition Syndromes: Leveraging Insights From High‐Risk Populations},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70674}
}
EUVIMED